Mitral Regurgitation - Valvular Heart Disease Guidelines

Valvular Heart Disease

ACC/AHA Valvular Heart Disease - Mitral Regurgitation GUIDELINES Apps brought to you charge courtesy of Guideline Central and Abbott Vascular.

Issue link: https://eguideline.guidelinecentral.com/i/362036

Contents of this Issue

Navigation

Page 46 of 59

45 Table 31B. Diagnosis and Treatment of IE (cont'd) Recommendations COR LOE TEE & TTE (cont'd) TEE is recommended in all patients with known or suspected IE when TTE is nondiagnostic, when complications have developed or are clinically suspected, or when intracardiac device leads are present. I B TTE and/or TEE are recommended for re-evaluation of patients with IE who have a change in clinical signs or symptoms (eg, new murmur, embolism, persistent fever, HF, abscess, or atrioventricular heart block) and in patients at high risk of complications (eg, extensive infected tissue/ large vegetation on initial echocardiogram or staphylococcal, enterococcal, or fungal infections). I B Intraoperative TEE is recommended for patients undergoing valve surgery for IE. I B TEE is reasonable to diagnose possible IE in patients with S. aureus bacteremia without a known source. IIa B TEE is reasonable to diagnose IE of a prosthetic valve in the presence of persistent fever without bacteremia or a new murmur. IIa B TEE might be considered to detect concomitant staphylococcal IE in nosocomial S. aureus bacteremia with a known portal of entry from an extracardiac source. IIb B Medical erapy Patients with IE should be evaluated and managed with consultation of a multispecialty Heart Valve Team including an infectious disease specialist, cardiologist, and cardiac surgeon. In surgically managed patients, this team should also include a cardiac anesthesiologist. I B Appropriate antibiotic therapy should be initiated and continued aer blood cultures are obtained, with guidance from antibiotic sensitivity data and infectious disease consultants. I B It is reasonable to temporarily discontinue anticoagulation in patients with IE who develop CNS symptoms compatible with embolism or stroke, regardless of other indications for anticoagulation. IIa B Temporary discontinuation of VKA anticoagulation might be considered in patients receiving VKA anticoagulation at the time of IE diagnosis. IIb B Patients with known VHD should NOT receive antibiotics before blood cultures are obtained for unexplained fever. III: Harm C

Articles in this issue

view archives of Mitral Regurgitation - Valvular Heart Disease Guidelines - Valvular Heart Disease